GVK BIO has entered an agreement to acquire Aragen Bioscience, Inc., a privately held U.S. based, preclinical CRO specializing in biologics services. GVK BIO is small molecule service provider in Asia. The acquisition expands GVK BIO’s service offering to a broader client base and provides expertise in biologics services, as well as a significant U.S. presence. Financial terms were not disclosed.
"As an increasing number of biotech and pharmaceutical companies focus on protein based therapeutics and biosimilars, the acquisition of Aragen Bioscience will strategically enhance GVK BIO’s ability to offer high quality R&D services to the industry from a seamless integrated platform,” said Mr. D. S. Brar, chairman, GVK BIO.
"Aragen’s scientific excellence and expertise in large-molecule R&D services combined with GVK BIO’s scale, resources, and global reach will create significant synergies for both companies,” said Rick Srigley, president and chief executive officer, Aragen Bioscience.
GVK BIO To Acquire Aragen Bioscience
By Kristin Brooks
Published January 29, 2014
blog comments powered by Disqus